Skip to main content
RADIOPHARM THERANOSTICS LIMITED logo

RADIOPHARM THERANOSTICS LIMITED — Investor Relations & Filings

Ticker · RAD ISIN · AU0000181851 ASX Professional, scientific and technical activities
Open in API
Filings indexed 447 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country AU Australia
Listing ASX RAD

About RADIOPHARM THERANOSTICS LIMITED

https://radiopharmtheranostics.com/

Radiopharm Theranostics Limited is a clinical-stage company specializing in the development of a diverse platform of radiopharmaceutical products for oncology. The company employs a theranostic strategy, integrating diagnostic imaging and targeted therapeutic agents to address various cancers with high unmet medical needs. Its pipeline features multiple proprietary assets, including PTPμ for brain tumors, αVβ6 Integrin for pancreatic and head and neck cancers, and LRRC15 for aggressive solid tumors. By utilizing radioisotopes such as Actinium-225, Lutetium-177, and Gallium-68, the company develops precision medicines designed to target specific biomarkers on cancer cells. These technologies aim to provide highly localized radiation therapy while sparing healthy tissue, advancing through clinical phases to improve outcomes for patients with complex malignancies.

Recent filings

Filing Released Lang Actions
Financial Services and Company Secretary Changes 2 pages 275.7KB
Regulatory Filings
2026-04-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 1.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities & Cash Report and 4C for the quarter ended 31 March 2026' and is an ASX announcement dated 23 April 2026. It provides a detailed business update including clinical trial progress, financial results for the quarter, and a cash flow statement in the form of Appendix 4C, which is a standard quarterly cash flow report required by the ASX Listing Rules 4.7B and 4.7C. The document contains substantive financial data such as cash flows from operating, investing, and financing activities, and detailed commentary on business activities and clinical trial progress. This matches the characteristics of an Interim / Quarterly Report (IR), which includes comprehensive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement of a report or a certification, but contains actual financial statements and business updates. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2026
2026-04-22 English
RAD Initial Findings from Phase 1 177Lu-RAD202 Trial 3 pages 136.7KB
Regulatory Filings Classification · 85% confidence The document is an ASX regulatory announcement detailing clinical trial findings and a poster presentation at a scientific conference. It does not announce financial results, capital changes, management changes, dividends, or any regulatory filing specifically covered by other categories. It is essentially a corporate news release to the exchange, so it falls into the fallback “Regulatory Filings” category.
2026-04-19 English
RAD Completes Enrollment in Phase 2b Trial of RAD 101 2 pages 355.3KB
Regulatory Filings Classification · 80% confidence The document is an ASX announcement regarding a clinical trial milestone (enrollment completion in a Phase 2b imaging trial) for Radiopharm Theranostics. It contains no financial results, no regulatory audit data, no share transactions, no board changes, and is not a proxy or investor presentation. It is a general corporate press release filed with the exchange that does not fit any of the specific financial report categories. Therefore it falls under the fallback “Regulatory Filings” category.
2026-04-15 English
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 2 pages 131.9KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated April 8, 2026, from Radiopharm Theranostics. It reports a positive recommendation from the Data Safety and Monitoring Committee to advance a Phase 1 clinical trial to the next dose level. The content focuses on clinical trial progress and safety updates rather than financial results, management changes, or regulatory filings. The document is relatively short (4091 characters) and is an announcement of clinical trial progress rather than a detailed report or financial statement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The best fitting category is Capital/Financing Update (CAP) because clinical trial progress announcements by biopharmaceutical companies are often classified under capital/financing updates as they relate to development milestones impacting company valuation and financing activities.
2026-04-07 English
RAD and Siemens Sign Clinical Supply Agreement for RAD101 2 pages 118.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 7 April 2026 from Radiopharm Theranostics regarding a clinical supply agreement with Siemens Healthineers for RAD101 in the U.S. It discusses clinical trial progress, partnership details, and future plans for a Phase 3 registrational trial. There are no financial statements, earnings data, or regulatory filings such as annual or interim reports. The content is focused on a business update about a supply agreement and clinical trial progress, which fits the category of a Capital/Financing Update or general corporate announcement. However, since it is specifically about a supply agreement related to clinical trial materials and not about fundraising or capital structure changes, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories. The document length is under 5,000 characters, and it is an announcement rather than a full report or transcript.
2026-04-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.